Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market 20262031
The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market was valued at in and is anticipated to reach by 2031, at a CAGR of 0.2231 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market.
This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Scope:
By Diagnostics Segment
This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market.
This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Scope:
By Diagnostics Segment
- Imaging Techniques
- Diagnostic Tests
- Biopsy
- Ocaliva
- Elafibranor
- Cenicriviroc
- Selonsertib
- Others
- Hospital Pharmacy
- Online Channel
- Retail Channel
- Abbvie Inc.
- Cadila Healthcare Limited
- Conatus Pharmaceuticals Inc.
- Exalenz Bioscience Ltd.
- Genfit SA
- Gilead Sciences Inc.
- Intercept Pharmaceuticals Inc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Quest Diagnostics
- Shire Plc
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- WuXi AppTec(List not Exhaustive)
This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. SCOPE AND METHODOLOGY
1.1. Research Methodology
1.2. Scope of the Market
2. KEY TRENDS AND DEVELOPMENTS
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Diagnostics
3.2. Market Snippet by Therapeutics
3.3. Market Snippet by Sales Channel
3.4. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market impacting factors
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Value chain analysis
5.3. Patent Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
7. BY DIAGNOSTICS
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%),
7.1.2. By DiagnosticsSegment
7.2. Market attractiveness index,
8. BY DIAGNOSTICS SEGMENT
8.1. Imaging Techniques *
8.1.1. Introduction
8.1.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
8.2. Diagnostic Tests
8.3. Biopsy
9. BY THERAPEUTICS
9.1. Introduction
9.1.1. Market size analysis, and y-o-y growth analysis (%), By Therapeutics Segment
9.1.2. Market attractiveness index, By Therapeutics Segment
9.2. Ocaliva *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
9.3. Elafibranor
9.4. Cenicriviroc
9.5. Selonsertib
9.6. Others
10. BY SALES CHANNEL
10.1. Introduction
10.1.1. Market size analysis, and y-o-y growth analysis (%), By Sales Channel Segment
10.1.2. Market attractiveness index, By Sales Channel Segment
10.2. Hospital Pharmacy *
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
10.3. Online Channel
10.4. Retail Channel
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key region-specific dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. South America
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.3.6.1. Brazil
11.3.6.2. Argentina
11.3.6.3. Rest of South America
11.4. Europe
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.4.6.1. Germany
11.4.6.2. U.K.
11.4.6.3. France
11.4.6.4. Spain
11.4.6.5. Italy
11.4.6.6. Rest of Europe
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
12. COMPETITIVE LANDSCAPE
12.1. Competitive scenario
12.2. Competitor strategy analysis
12.3. Market positioning/share analysis
12.4. Mergers and acquisitions analysis
13. COMPANY PROFILES
13.1. Abbvie Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Cadila Healthcare Limited
13.3. Conatus Pharmaceuticals Inc.
13.4. Exalenz Bioscience Ltd.
13.5. Genfit SA
13.6. Gilead Sciences Inc.
13.7. Intercept Pharmaceuticals Inc.
13.8. Merck & Co., Inc.
13.9. Novartis AG
13.10. Novo Nordisk A/S
13.11. Quest Diagnostics
13.12. Shire Plc
13.13. Siemens Healthineers
13.14. Thermo Fisher Scientific Inc.
13.15. WuXi AppTec(*List not Exhaustive*)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About us and services
14.3. Contact us
1.1. Research Methodology
1.2. Scope of the Market
2. KEY TRENDS AND DEVELOPMENTS
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Diagnostics
3.2. Market Snippet by Therapeutics
3.3. Market Snippet by Sales Channel
3.4. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market impacting factors
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Value chain analysis
5.3. Patent Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
7. BY DIAGNOSTICS
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%),
7.1.2. By DiagnosticsSegment
7.2. Market attractiveness index,
8. BY DIAGNOSTICS SEGMENT
8.1. Imaging Techniques *
8.1.1. Introduction
8.1.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
8.2. Diagnostic Tests
8.3. Biopsy
9. BY THERAPEUTICS
9.1. Introduction
9.1.1. Market size analysis, and y-o-y growth analysis (%), By Therapeutics Segment
9.1.2. Market attractiveness index, By Therapeutics Segment
9.2. Ocaliva *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
9.3. Elafibranor
9.4. Cenicriviroc
9.5. Selonsertib
9.6. Others
10. BY SALES CHANNEL
10.1. Introduction
10.1.1. Market size analysis, and y-o-y growth analysis (%), By Sales Channel Segment
10.1.2. Market attractiveness index, By Sales Channel Segment
10.2. Hospital Pharmacy *
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
10.3. Online Channel
10.4. Retail Channel
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key region-specific dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. South America
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.3.6.1. Brazil
11.3.6.2. Argentina
11.3.6.3. Rest of South America
11.4. Europe
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.4.6.1. Germany
11.4.6.2. U.K.
11.4.6.3. France
11.4.6.4. Spain
11.4.6.5. Italy
11.4.6.6. Rest of Europe
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
11.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
12. COMPETITIVE LANDSCAPE
12.1. Competitive scenario
12.2. Competitor strategy analysis
12.3. Market positioning/share analysis
12.4. Mergers and acquisitions analysis
13. COMPANY PROFILES
13.1. Abbvie Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Cadila Healthcare Limited
13.3. Conatus Pharmaceuticals Inc.
13.4. Exalenz Bioscience Ltd.
13.5. Genfit SA
13.6. Gilead Sciences Inc.
13.7. Intercept Pharmaceuticals Inc.
13.8. Merck & Co., Inc.
13.9. Novartis AG
13.10. Novo Nordisk A/S
13.11. Quest Diagnostics
13.12. Shire Plc
13.13. Siemens Healthineers
13.14. Thermo Fisher Scientific Inc.
13.15. WuXi AppTec(*List not Exhaustive*)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About us and services
14.3. Contact us
